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Endometrial cancer is themost common gynecologic malignancy in developed countries.
Estrogen-dependent tumors (type I, endometrioid) account for 80% of cases and
non-estrogen-dependent (type II, non-endometrioid) account for the rest. Endometrial
cancer type I is generally thought to develop via precursor lesions along with the
increasing accumulation of molecular genetic alterations. Endometrial hyperplasia with
atypia/Endometrial Intraepithelial Neoplasia is the least common type of hyperplasia
but it is the type most likely to progress to type I cancer, whereas endometrial
hyperplasia without atypia rarely progresses to carcinoma. MicroRNAs are a class of
small, non-coding, single-stranded RNAs that negatively regulate gene expressionmainly
binding to 3′-untranslated region of target mRNAs. In the current study, we identified a
microRNAs signature (miR-205, miR-146a, miR-1260b) able to discriminate between
atypical and typical endometrial hyperplasia in two independent cohorts of patients.
The identification of molecular markers that can distinguish between these two distinct
pathological conditions is considered to be highly useful for the clinical management of
patients because hyperplasia with an atypical change is associated with a higher risk
of developing cancer. We show that the combination of miR-205, −146a, and −1260b
has the best predictive power in discriminating these two conditions (>90%). With the
aim to find a biological role for these three microRNAs, we focused our attention on
a common putative target involved in endometrial carcinogenesis: the oncosuppressor
gene SMAD4. We showed that miRs-146a,−205, and−1260b directly target SMAD4
and their enforced expression induced proliferation and migration of Endometrioid
Cancer derived cell lines, Hec1a cells. These data suggest that microRNAs-mediated
impairment of the TGF-β pathway, due to inhibition of its effector molecule
SMAD4, is a relevant molecular alteration in endometrial carcinoma development.
Giglio et al. miRNAs as Biomarker of AH/EIN
Our findings show a potential diagnostic role of this microRNAs signature for the accurate
diagnosis of Endometrial hyperplasia with atypia/Endometrial Intraepithelial Neoplasia
and improve the understanding of their pivotal role in SMAD4 regulation.
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INTRODUCTION
Worldwide, endometrial cancer (EC) represents 4% of all
cancers in women and is the most common malignant tumor
of the female genital tract in industrialized countries (1).
The etiology of EC is not yet fully understood, although
there is some evidence that molecular modifications
and hormonal influences contribute to its initiation and
progression (2).
Endometrial cancer is divided into two major classes:
estrogen-dependent tumors (type I, endometrioid endometrial
carcinomas) that represent 80% of cases and non-estrogen-
dependent (type II, non-endometrioid endometrial carcinomas)
that account for the rest. EC type I is thought to develop via
precursor lesions along with the increasing accumulation of
molecular genetic aberration (3, 4).
Recently, the World Health Organization classification of
tumors (WHO) (5) divided endometrial hyperplasias into two
categories: hyperplasia without atypia (Benign Hyperplasia, BH)
and atypical hyperplasia/endometrioid intraepithelial neoplasia:
(AH/EIN) (5).
Indeed, AH/EIN is most likely to progress to type I
endometrial carcinoma (∼30%), and has been reported to be
associated with invasive EC in 62% of endometrial biopsy (6),
whereas BH rarely progresses to EC (<5%) (7). Therefore,
discerning between these two entities has significant clinical
implications (8).
Unfortunately, recognition of atypia in endometrial
hyperplasia is subjective among pathologists with a low
inter observer reproducibility (<50% in almost all studies)
(9, 10).
Although the recent two-tier classification of these
entities by WHO (5, 11) improved reproducibility,
management of endometrial pre-cancers is compromised
by a longstanding debate.
MicroRNAs (miRs) are a class of small, non-coding, single-
stranded RNAs that negatively regulate gene expression mainly
binding to 3′-untranslated region (UTR) of target mRNAs at
the post-transcriptional level (12). Several studies showed that
they are important in many biological processes, thus their
aberrant expressions are closely associated with the development,
invasion, metastasis, and prognosis of various cancers, including
EC (13–17).
Up until now, several miR signatures have been documented
in either normal or neoplastic endometrium, but the role of miRs
in endometrial hyperplasia with or without atypia remains poorly
understood (18–22). In the present study, we investigate the
hypothesis that changes inmiRsmay represent useful biomarkers
for the diagnosis of AH/EIN.
MATERIALS AND METHODS
Endometrial Tissue Samples and Patients
Eighty-five archived formalin-fixed, paraffin embedded (FFPE)
tissue blocks of BH (41 cases), and AH/EIN (44 cases),
were obtained from the Pathology Department of Sant’Andrea
Hospital and Ospedale Cannizzaro, Catania from 2004 to 2013.
Patient’s age ranged from 37 to 84 years, with a median of
56 years. This study was authorized by the institutional ethics
committee board at S. Andrea Hospital Rome, Italy (Aut.
#168/03). Written informed consent was obtained from all
patients enrolled.
The selected cases were randomly divided into a training
set (23 BH, 19 AH/EIN) and into a validation set (21 BH,
22 AH/EIN).
Hyperplasia was macro or laser-microdissected, were
appropriate, for this study.
RNA Extraction
Total RNA, including miRs fraction, was extracted from
FFPE tissues using the High Pure miRNA isolation kit
(Roche) according to the manufacturer’s instructions. RNAs
concentration were assessed using Nanodrop (ThermoScientific).
Affymetrix Gene Chip miRNA Array
RNA quality and purity were assessed with the use of the
RNA 6000 Nano assay on Agilent 2100 Bioanalyzer (Agilent).
Briefly, 500 ng of total RNA was labeled using FlashTag
Biotin HSR (Genisphere LLC) and hybridized to GeneChip R©
miRNA 2.0 Arrays. The arrays were stained in the Fluidics
Station 450 and then scanned on the GeneChip R© Scanner 3000
(Affymetrix, USA).
Microarray Data Analysis
The statistical analysis was performed by Transcriptome Analysis
Console (TAC) software (Thermo Fisher Scientific).
To survey outliers that could disturb the dataset, a Principal
Component Analysis (implemented by means of R statistical
software) was performed and its visualization, which led to
the knowledge of which subjects needed to be excluded
from the dataset. MicroRNA probe outliers were defined
from the manufacturer’s instructions (Affymetrix, USA), and
further analysis included data summarization, normalization,
and quality control using the web-based miRNA QC Tool
software (Affymetrix).
The microarray data has been submitted and assigned a GEO
omnibus accession number GSE85105.
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Reverse Transcription and Quantitative
Real-Time PCRs
Each sample was reverse-transcribed using miRNA
miRCURY LNA Universal RT kit (Exiqon) according to
the manufacturer’s protocol.
Reverse transcription and quantitative real-time PCRs were
performed for miRNAs using miRCURY LNA Universal RT
microRNA PCR LNA primers set with miRCURY LNA cDNA
Synthesis Kit II and ExiLENT Syber Green master mix, in
triplicate (Exiqon). RNU48 (U48) was used to normalize input
total small RNA.
Expression of each miR was presented as the ratio between
miR and RNU48 (RQ). The relative miRs expression was
calculated using the 11Ct method. At least three separate
experiments were performed, and each sample was assayed
in triplicate.
Cells Transfections
Pre-designed Pre-miR (miR Precursors) for each miR
was obtained from Ambion (ThermoFisher Scientific). A
negative-control miRNA mimic [Pre-miR miRNA negative
#1 (Ambion, ThermoFisher Scientific)] was used to address
the specificity of the observed effect to the specific miR
sequence. Cells were transfected using Lipofectamine RNAimax
(ThermoFisher Scientific).
Protein Extraction, Western Blotting, and
Antibodies
Hec1a cell lines were obtained from ATCC (Atcc, HTB-112)
and cultured according to the manufacturer’s protocol. Total
cell extracts with RIPA buffer (Sigma Aldrich) were collected at
24 h and analyzed by western blot to assess proteins expression
levels. Briefly, Hec1a cells were rinsed in ice-cold PBS and
subsequently lysed in ice-cold RIPA lysis buffer (Sigma Aldrich)
and Complete inhibitor (Roche). Proteins were analyzed on pre-
cast polyacrylamide gel (Bio-Rad), transferred onto nitrocellulose
membranes (Bio-Rad) and blocked with 5% BSA (Sigma
Aldrich), and incubated with specific primary antibodies.
Polyclonal antibody against SMAD4 (sc-7966, Santa Cruz
Biotechnology) diluted 1:200. Monoclonal antibody against
PAX2 (aJ1589a, Abgent) diluted 1:1,000. Monoclonal antibody
against Pten (560002, BD Biosciences) diluted 1:1,000.
To normalize protein loading, membranes were probed for 1 h
at room temperature with an anti-vinculin antibody (sc- 25336,
Santa Cruz Biotechnology).
Secondary antibodies (labeled HRP anti-rabbit or anti-mouse,
Bio-Rad) were incubated for 45min at room temperature and
revealed with chemiluminescent ECL method (Bio-Rad).
Digital images of autoradiography were acquired with
ChemiDOC XRS (Bio-Rad).
Plasmids and Constructs
The 3′UTR of the SMAD4 gene was obtained from GeneArt
Gene Synthesis (Invitrogen, Thermo Fisher Scientific) by cloning
900bp of SMAD4 3′UTR into pMir-vector (Promega) giving rise
to the pMir-3′UTRSMAD4 construct.
Site-direct mutagenesis into the miR-205, miR146a, and miR-
1260b binding sites of the SMAD4 gene 3′UTR were introduced
using GeneArt Site-Directed Mutagenesis PLUS System
kit (Thermo Fisher Scientific) according to manufacturer’s
instructions. The primers used were:
FP 5′CTTCACCTGTTATGTAcctgccAATCATTCCAGT
GC3′
RP 5′GCACTGGAATGATTggcaggTACATAACAGGTG
AAG3′
FP 5′GCTGATTTTAAAGGCAGAGAAccgtcgAAAGTTA
ATTCACC3′
RP 5′GGTGAATTAACTTTcgacggTTCTCTGCCTTTA
AAATCAGC3′
FP 5′GTTATTCCTAGTGacccgtTGTTGATGAAGTAT
ACTTTTCCCC3′
RP 5′GGGGAAAAGTATACTTCATCAACAacgggtCACTA
GGAATAAC3
Luciferase Activity Assays
Hec1a cells were cultured in 12-well-plates and transfected
with 500 ng of pMir-3′UTRSMAD4 wt or mutated plasmid
or pMir control vector together with 50 ng of β-GAL
vector and 50 pmoles of pre-miR-205, pre-miR-146a, pre-
miR-1260b, or pre-miR-negative control#1 (Thermo Fisher
Scientific). Transfections were carried out using Lipofectamine
2000 and OPTI-MEM as recommended by the manufacturer
(Thermo Fisher Scientific). At 48 h after transfection, luciferase
activity was measured using the Luciferase Reporter Assay
(Promega). Each transfection was repeated twice in triplicate.
Transfection efficiency was corrected to β-GAL expression in
all cases.
Cell Proliferation Assay
Cell proliferation was measured using Muse R© Count & Viability
Assay Kit and Muse R© Cell Analyzer as recommended by the
manufacturer (MerckMillipore). Cells were transfected with each
pre-miR and the pre-miR-negative control#1 into a 35mm dish
as described below and incubated for 72 h. Three independent
experiments were performed in duplicate.
Transwell Migration Assay
The migration ability of Hec1A cells was determined in a Boyden
Chamber. Twenty-four hours after transfection, the cells were
seeded into 8µm Transwells (6.5mm diameter, Corning) at
5 × 104 cells well with serum-free culture medium. Medium
containing 10% FBS was added into the lower chamber and
served as the chemoattractant. After incubation for 24 h, the
cells remaining on the upper surface of the filter were removed
by gently wiping with a cotton swab. The cells migrated
through the filter were fixed with methanol, stained with MGG
quick staining (Bio Optica), and visualized by an inverted
fluorescence microscope.
Statistical Analysis
Data were expressed as the mean ± SD from at least
three independent experiments. Statistical analysis between
two samples was performed using Student’s t-test. Statistical
comparisons of more than two groups were performed using
one-way analysis of variance (ANOVA).
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FIGURE 1 | Hierarchical clustering. (A,B) Representative H/E stain images of BH and AH (Magnification 20X). (C) Heat Map depicting hierarchical cluster analysis of
the 14 miRs differentially expressed between AH/EIN (A) and BH (T) identified by microarrays analysis.
The diagnostic ability of miRs-205, −146a, and −1260b
in diagnosing atypical hyperplasia was examined via the area
under the corresponding receiver operating characteristic curve
(AUC). All statistical analyses were performed using Graph Pad
Prism software (GraphPad software). p < 0.05 was considered
statistically significant.
RESULTS
Dysregulated miRs in BH vs. AH/EIN
To investigate whether miRs could discriminate BH from
AH/EIN, we analyzed the expression of 1,105 human miRs
(miRbase version 15) in the training set (23 BH, 19 AH/EIN).
Examples of BH and AH are presented in Figures 1A,B.
As shown in Figure 1C, we could identify 14 differentially
expressed miRs capable of discriminating BH from AH/EIN
(FC ≥ 1.5, p ≤ 0.05). In particular, 13 miRs were upregulated
(miRs-205,-146a, −200b_star, −1274a, −1260b, −200b, −200a,
−192, −183, −10, −194, and −200a_star) and 1 (miR-379) was
downregulated in AH/EIN compared to BH samples.
Using multiple logistic regression, the statistical significant
variables (Age, BMI, Parity, miR values) were assessed in
univariate analysis and investigated comparing BH to AH/EIN.
No significant correlation was observed (data not shown).
Differentially expressed miRs were then validated in an
independent validation set (21 BH, 22 AH/EIN). Out of the
14 miRs initially identified, we could confirm three miRs
all up-regulated (miR-205, −146a, and −1260b) (Figure 2A),
suggesting that these miRs could discriminate between the
two groups.
To assess the ability of each miR to differentiate between
AH/EIN and BH, receiver-operating characteristic curves (ROC)
were constructed and the area under the curve (AUC) was
calculated. Univariate analysis for each individual miR showed
an AUC of 0.8 [95% confidence interval (CI) = 0.66–0.93 p =
0.0009] for miR-205, an AUC of 0.8 (95% CI = 0.68–0.94 p =
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FIGURE 2 | Validation and ROC curve analysis of identified miRs. (A) Validated differentially expressed miRs are shown. Expression levels of miRs-205,−146a,
and−1260b were significantly higher in AH/EIN compared with BH. The horizontal lines indicate the median value. **p ≤ 0.01, ***p ≤ 0.001. (B,C) Accuracy for each
and for the combination of the three miRs in differentiating AH/EIN from BH, respectively. AUC is shown. All p ≤ 0.05.
0.0008) for miR-146a, and an AUC of 0.9 (95% CI = 0.88–1.01 p
< 0.0001) for miR-1260b, respectively (Figure 2B). Performing
a multivariate analysis for the combination of the three miRs,
we observed an AUC of 0.95 (95% CI 0.88–1.01 p < 0.0001)
showing that these three miRs have a high predictive power in
discriminating AH/EIN from BH (Figure 2C).
SMAD4 Is a Target of miRs-205, 146a, and
1260b
To investigate a biological role for these miRs in AH/EIN, we
searched different prediction algorithms. We found that highly
conserved binding sites for each of these miRs were present in
the mRNA of the oncosuppressor gene SMAD4, which has been
shown to be down-modulated in EC (23).
We used endometrial cancer-derived cell lines Hec1a and
tested the endogenous expression of these miRs.
QRT-PCR analysis showed that Hec1a cells expressed
detectable amounts of each miRs (Figure 3A). To investigate
the effects of these miRs on SMAD4 expression, we transiently
transfected pre-miRs-146a, −205, and −1260b or control into
Hec1a cells.
In miRs transfected cells, we observed a significant
suppression of SMAD4 compared to control (Figure 3B).
To further confirm this observation, we transiently transfected
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FIGURE 3 | miRs-205,−146a, and−1260b regulate SMAD4 levels. (A) Expression levels of each miR were assessed in Hec1a cell line. Relative expression of
miRs-205,−146a, and−1260b is reported. Each Ct value is normalized to RNU48. (B) Hec1a cells transfected as showed. The Smad4 protein appears as a band at
approximately 60 kDa. Actin (∼40 kDa) was used as a loading control LC. Densitometry value is reported under each line. (C) RT-PCR verification of the transfection
efficiency of Hec1a cells transfected in B. Each bar shows miR expression normalized to RNU48 ±SD of three independent experiments.
Hec1a cells with antagomirs. This resulted in an increase
of SMAD4 levels, compared to control (Figures 3B,C),
as expected.
Co-loss of both PTEN and PAX2 has been reported in
AH/EIN and it has been regarded as the reference markers for
its diagnosis (24).
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Therefore, we analyzed Pax2 levels by Western blot and we
observed a strong protein reduction in miR-1260b transfected
cells. There is no evidence of interaction between these two
players, but miR binding sites algorithm prediction showed
that other Pax family members are the putative target of miR-
1260b. We also found that pTEN was downregulated in miR-
205 transfected cells confirming previous evidence showing the
potential role of miR-205 in regulating PTEN in endometrial
tissue (25).
Although by different means, Smad4 could be a target
of these miRs, one can argue that miR-146a, miR-205, and
miR-1260b interact with other unknown targets that down-
regulate Smad4 protein levels (18–22) (Figure 4A). To address
this concern, we performed a luciferase reporter assay, cloning
a 900 bp 3′UTR of human SMAD4 into a pMIR vector
(p3′UTRSmad4pMir). Therefore, Hec1a cells were transfected
either with miR-146a, miR-205, mir-1260b, or the pre-miR-
control, and p3′UTRSmad4pMir vector. As shown in Figure 4B,
all miRs decrease luciferase activity of the p3′UTRSmad4pMir
compared to control, showing that each miR has a direct
effect on their target in this cell lines (Figure 4B). To
determine this direct miR-target interaction, we constructed
a plasmid with mutagenesis of the three seed sequences
(Figure 4C). As expected, we observed only a slight effect
on luciferase activity when we compared the wild-type vector
with the p3′UTRSmad4pMir mutants in the presence of
each miRs overexpressed, showing that the modification of
the seed sequence is enough to block the function of each
miR (Figure 4C).
SMAD4 Repression by miRs-205, 146a, and
1260b Induces Proliferation and Migration
in Hec1a Cell Lines
Smad4 is involved in the signal transduction pathway of the
transforming growth factor ß (TGF-ß) that acts as a tumor
suppressor gene in several cancers (26, 27). To gain further
insights into how dysregulation of these miRs may play a role in
endometrial cancer cells, we performed different assays to study
the biological effects of the interaction between these miRs and
their target Smad4 into endometrial adenocarcinoma-derived cell
lines Hec1a.
First, we tested cells proliferation. Cells transfected with
pre-miRs-146a, −205, or −1260b showed a higher rate of
proliferation compared with non-treated or control transfected
cells (Figure 5A). Cells transfected with anti-miRs-146a, −205,
or −1260b showed a reduction of proliferation compared to
control (Figure 5B).
To better understand how the dysregulation of these miRs
may change the behavior of endometrial cancer-derived cell
line, we examined the influence of Smad4 knockdown on
Hec1a cell migration. We found a significant increase in
the migration capability in pre-miR-205, −146a, or −1260b
transfected cells compared to control, showing that these miRs
positively regulate the migration of cultured endometrial cancer
cells (Figures 5C,D).
Since miRs may have multiple targets, to ensure that Smad4
mediated the observed effects, we repeated the assay using a
specific Smad4 siRNA.
We confirm significant down-regulation of Smad4 through
qRT-PCR (Figure 5E). Next, we observed that Hec1a cells
transfected with Smad4 siRNA displayed a higher proliferation
and migration rate respect to controls (Figures 5C,F).
DISCUSSION
Identification of molecular markers that can differentiate
between AH/EIN and BH are considered to be highly useful
for clinical management of patients because hyperplasia
with atypical change and/or Endometrial Intraepithelial
Neoplasia are associated with a higher risk to progress to
cancer (4).
Since there aren’t reference markers, the diagnosis is based
only on histological features, such as the presence of nucleoli
and other atypical characteristics, which are not consistently
associated with that diagnosis (9).
Although the new WHO classification is more likely to
successfully identify premalignant lesions, the low interobserver
reproducibility among gynecological pathologist in diagnosing
atypical hyperplasia/EIN should be improved (6, 10, 28–30).
Atypical endometrial hyperplasia/EIN and EC shares several
molecular alterations with each other, including microsatellite
instability, PAX2 inactivation, mutation of PTEN, KRAS, and
CTNNB1 (β-catenin), but there is not a linear accumulation of
mutational events leading to cancer (31). Identifying the disease-
related miRs will improve the diagnosis and understanding of
pathogenesis of these lesions.
Since over 50% of miRs reside in cancer-associated genomic
regions, they have been indicated to play an important role as
diagnostic biomarkers (13, 32, 33).
Most of the miRs studies on endometrium have been focused
on the identification of their implications in EC development,
almost neglecting their possible diagnostic role in precursor
lesions (34). In fact, several authors showed an altered expression
of miRs that may discriminate EC from non-atypical or atypical
hyperplasia (9, 14, 21, 35–40).
In particular, expression of five miRs (miRs-182, 183, 200a,
200c, and 205) was significantly higher in EC when compared
with complex atypical hyperplasia, simple hyperplasia (SH) and
normal endometrial tissue (P < 0.05, respectively) (41).
To our knowledge, our study is the first to identify a miRs
signature able to discriminate between atypical hyperplasia/EIN
and benign endometrial hyperplasia with the capability to better
distinguish between low- and high- risk lesions. Identification of
miR-target genes and pathways to understand themolecular basis
of endometrial cancer pathogenesis is a major challenge, as there
are numerous pathways that drive cancer. Accordingly, in this
study, we proposed a novel miR-based classification method to
categorize the high risk pre-cancerous endometrial lesions.
In fact, we showed a high predictive power, above
90%, using a three miRs-signature (miRs-146a, −205, and
−1260b) in distinguishing between non-atypical and atypical
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FIGURE 4 | SMAD4 is a target of miRs-205, −146a, and −1260b. (A) Schematic representation of predicted miRs binding sites in the SMAD4 3′UTR. (B) Luciferase
reporter assay in Hec1a cells co-transfected with the reporter gene containing the SMAD4 3′UTR alone (pmiRSMAD4 3′UTR) (gray bar), the SMAD4 3′UTR and
miRs-205, −1260b, and −146a (light gray bars), respectively and the negative control (CTRL) (black bar). Each reporter plasmid was transfected three times, and
each sample was assayed in triplicate. (C) Luciferase reporter assay performed in Hec1a cells co-transfected with the reporter gene containing the SMAD4 3′UTR
mutated (pmiRSMAD4 3′UTR-Mut) in the miRs-205, −146a, or −1260b seed sequences (gray bar) alone, the pmiRSMAD4 3′UTR-Mut in each mir seed sequence
and miRs-205, −1260b, and −146a (light gray bars), respectively and the negative control (CTRL) (black bar). Bars indicate Firefly Luciferase activity normalized to
β-Gal activity ±SD. *p ≤ 0.05 compared to control (CTRL) transfected cells.
hyperplasia/EIN provides a supplementary diagnostic tool
when required.
Interestingly, a previous study conducted by Snowdon and
colleagues examined a miRs profile in atypical hyperplasia
compared to normal proliferative controls. The microarray
expression profile shares some important similarities with our
data. MiRs-146a, miR-200a, miR-200b, miR-200b-star, and miR-
205 resulted up-regulated and miR-542-5p down-regulated in
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FIGURE 5 | SMAD4 regulation by miRs-205, −146a, and −1260b induces proliferation and migration in Hec1a cells. (A,B) Hec1a cells proliferation was measured at
72 h. Cells were transiently transfected with negative control #1 (C) and miRs-205, −146a, −1260b in A or anti-miRs-205, −146a, and −1260b (a-miRs) in
B. (C) Transwell migration assay shows that overexpression of miRs-205, −146a, −1260b, and siSMAD4 enhance cell migration ability of Hec1a cells. (D)
Representative photographs of the Transwell migration assay is shown. All data are presented as mean ± SD, *p < 0.05. (E,F) Effects of siSMAD4 expression in
Hec1a cells. (E) RT-PCR (upper panel) and western blot analysis (lower panel) are shown. LC (loading control, β-actin). PCR bars depict SMAD4 expression in control
(ctrl) and si transfected cells normalized to β-actin. (F) Measure of Hec1a cells proliferation in siSMAD4 and SiCTRL transfected cells is reported. Data represent the
mean (from three independent experiments) ±SD. *P < 0.05.
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atypical hyperplasia vs. normal endometrium, adding further
emphasis to our results (22). The up-regulation of miR-200
family members and miR-205 in EC is observed among different
studies, indicating that these miRs may play a role in driving
oncogenesis in the endometrium (21, 35, 37, 42, 43).
Some authors showed that miR-205 is a negative prognostic
marker for EC and its levels were significantly increased in
endometrial cancer cell lines and endometrial tumors compared
to normal tissues (25, 26). Mir-205 is directly involved in
PTEN regulation that represents one of the most commonly
investigated markers implicated in endometrial tumorigenesis
(44). Our results have enforced this effect indicating a remarkable
influence ofmiR-205 on regulating essential target genes involved
in different signal pathways in endometrial cells. On the other
hand, Lacey et al. have shown that a loss of expression of PTEN
status was not associated with progression risk of endometrial
hyperplasia (45).
Even if EC seems to be characterized by elevated expression
of miR-205, a recent study conducted by Wilczynski showed that
higher levels of miR-205may be amarker of an early stage disease
and is associated with a more favorable prognosis, whereas
patients with lower levels of miR-205 had worse survival (42).
No evidence has revealed the dysregulation of miRs-1260b
and −146a in EC, suggesting that up-regulation of these miRs
may be specific of AH/EIN.
Interestingly, authors found that a single nucleotide
polymorphism (SNP) rs2910164 G>C within miR-146a is
associated with the increased risk of gastric cancer and papillary
thyroid carcinoma (46, 47). A recent publication showed
that overexpression of miR-146a inhibited cell proliferation,
enhanced apoptosis, and increased sensitivity to chemotherapy
drugs in epithelial ovarian cancers cells showing, therefore, that
the role of miR-146a is still to be elucidated (48).
MiR-1260b has been found to be highly expressed in the
prostate, renal cell, and in colorectal carcinomas (49, 52).
Recently, it was demonstrated that in Hepatocellular carcinoma,
MiR-1260b promotes cell migration and invasion through the
G-protein signaling 22 (50).
All of this evidence confirmed that our identified miRs
regulate genes involved in different signal pathways that may
trigger the endometrial cellular transformation.
Thus, we investigated a possible common pathway that could
be regulated by these miRs and could be implicated in cellular
transformation, and we found that they target SMAD4. Also
noteworthy are several other reports, which demonstrated a
direct interaction of these miRs and this transcript (51–53).
Smad4 is a gene implicated in several cancers, including
EC, albeit its role in endometrial carcinogenesis is yet not
clear (54–56).
Impairment of the Smad pathway results in escape from
growth inhibition and leads to the promotion of cell proliferation,
contributing to carcinogenesis (57).
The disturbances in Smad proteins expression and/or
differences in their intracellular distribution, that trigger a
TGF-β signaling pathway deregulation, it was reported in
endometrial carcinomas, but it is still not well-understood (58).
The region within 18q21 where Smad4 is located is frequently
deleted in endometrial carcinomas, showing its involvement
in EC, however, an immunohistochemical study showed that
inactivation of this gene occurs infrequently in this tumor.
Changes in the expression of the TGF-β signaling cascade
in type I ECs seem to be associated mainly with deregulation
of TGF-β receptors and SMAD expression at the protein level,
indicating SMAD4 as a central molecule of this pathway (59, 60).
Thus, the potential pathogenic role of SMAD4 in endometrial
hyperplasia is supported by our finding, albeit further studies
are required to understand its biological and diagnostic role in
this environment.
Our results clearly demonstrated that overexpression of miRs-
146a, −205, and −1260b induced Hec1a proliferation and
migration through SMAD4 inhibition, providing an insight into
the possible mechanisms underlying the function of these miRs
in endometrial hyperplasia.
Thus, our work highlights the relevance of miRs in regulating
cellular processes that may ultimately lead to tumorigenesis.
Taken together these results strongly show that miRs-205,
−146a, and −1260b contribute to enhancing proliferation
and migration properties of endometrial cancer cells through
Smad4 inhibition.
In conclusion, distinguishing between hyperplasia and
true pre-cancerous lesions has significant clinical implications
because distinct endometrial pre-cancerous conditions require
intervention. Thus, we proposed a three miR-signature (146a
−205,−1260b) as a potential biomarker for diagnosis of atypical
endometrial hyperplasia/EIN that could have a significant impact
on treatment decisions. Furthermore, the regulatory capability
of these three miRs on cell proliferation and migration, possibly
through impairment of TGF-β signaling Smad4-mediated,
highlights their crucial role in endometrial hyperplasia outcome.
Although we believe that this study represents a step
forward in investigating the molecular relationship between miR
deregulation and EIN lesions, we analyzed a relatively small
group of patients, and therefore, a prospective analysis is needed
to strengthen the accuracy of our results.
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